Benign prostatic hyperplasia (BPH) without lower urinary tract symptoms (LUTS) refers to the histological and anatomical enlargement of the prostate gland in the absence of clinical voiding dysfunction. The prostate, a walnut-sized gland that surrounds the urethra, often undergoes non-malignant cellular proliferation as men age. In the case of N40.0, the diagnosis is typically made during a routine physical examination, such as a digital rectal exam (DRE), or incidentally through imaging studies like ultrasound or MRI, even though the patient does not report obstructive or irritative urinary symptoms. At this stage, the condition is often managed through watchful waiting or active surveillance, as the anatomical enlargement has not yet reached a threshold of mechanical obstruction or detrusor muscle irritation sufficient to cause symptoms like frequency, urgency, or nocturia.
Explicitly document the absence of lower urinary tract symptoms to support N40.0 coding.
Example: Patient presents for annual wellness exam. Physical examination reveals an enlarged, non-tender prostate on digital rectal exam. Patient denies any urinary frequency, urgency, hesitancy, or nocturia. Current International Prostate Symptom Score is 0. Assessment: Benign prostatic hyperplasia without lower urinary tract symptoms. Plan: Periodic monitoring via annual DRE and PSA screening.
Billing Focus: Documentation must specify the absence of LUTS to distinguish N40.0 from N40.1, ensuring correct ICD-10-CM code assignment.
Record prostate volume and consistency even in asymptomatic patients.
Example: Incidental finding on pelvic CT for abdominal pain: Prostate measures 45cc, which is enlarged for age, but shows no suspicious lesions. Patient reports normal voiding patterns and denies symptoms of bladder outlet obstruction. Diagnosis: Benign prostatic hyperplasia without lower urinary tract symptoms. Follow-up: Routine urology referral for baseline evaluation.
Billing Focus: Laterality is not applicable for the prostate gland, but size documentation provides clinical evidence for the diagnosis of hyperplasia.
Utilize standardized symptom scoring to objectively confirm the absence of symptoms.
Example: A 62-year-old male evaluated for prostatic enlargement noted during screening. IPSS score calculated at 4, categorized as mild/asymptomatic. Patient denies bother or lifestyle impact. Documentation: Benign prostatic hyperplasia without lower urinary tract symptoms. No surgical or pharmacological intervention required at this time.
Billing Focus: The IPSS score provides objective quantitative data to justify the use of N40.0 rather than a symptom-based code.
Distinguish between N40.0 and N40.2 when nodularity is present.
Example: Digital rectal exam shows a smooth, symmetrically enlarged prostate without nodules. Patient denies LUTS. Coding assigned: N40.0 Benign prostatic hyperplasia without lower urinary tract symptoms. Rationale: No nodularity noted on exam to support N40.2.
Billing Focus: Clinical exam findings like the presence or absence of nodules determine whether N40.0 or N40.2 is the more specific code.
Link secondary findings like elevated PSA to the BPH diagnosis when appropriate.
Example: Patient with PSA of 4.2 ng/mL. Repeat DRE confirms enlarged prostate. Transrectal ultrasound shows 50g gland without focal masses. Patient is asymptomatic with no urinary complaints. Diagnosis: Benign prostatic hyperplasia without lower urinary tract symptoms and elevated PSA. Plan: Monitoring every 6 months.
Billing Focus: Linking the asymptomatic BPH to the lab findings justifies the ongoing surveillance and medical necessity for diagnostic imaging.
Standard for routine follow-up of stable, asymptomatic BPH where management is low risk (watchful waiting).
Used when a patient is first referred to urology for an incidental finding of an enlarged prostate.
Used to objectively measure prostate volume and screen for lesions in asymptomatic patients with BPH.
Key laboratory test used alongside N40.0 to monitor for progression or malignancy.
Performed if N40.0 is associated with rising PSA to rule out occult malignancy.
Used to ensure that asymptomatic BPH is not causing silent urinary retention.
Used for direct visualization of the prostatic urethra if imaging is inconclusive.
Appropriate for brief checks of stable asymptomatic patients with no changes in history.
Quick assessment of the prostate and bladder in an outpatient setting.
Specific HCPCS code for Medicare screening that often results in the N40.0 diagnosis.